Tenet Healthcare stock rises 2% on earnings beat and raised guidance
Tenet Healthcare (NYSE:THC) reported Q3 2026 adjusted EPS of $6.64, beating estimates by $1.97. Revenue was $5.63B, up 6.5% YoY. The company raised full-year 2026 adjusted EBITDA guidance to $5.05B-$5.20B and adjusted free cash flow guidance to $2.825B-$3.125B. Shares rose 2.05% in pre-market trading.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are likely to attract buying interest, supporting a near‑term price rally.
Market read
Strong earnings and guidance raise make THC a short‑term buying candidate.
What to watch
Potential headwinds from regulatory changes or payer mix shifts are not addressed in the release.
Background
Tenet Healthcare (NYSE:THC) posted Q3 2026 results with adjusted EPS $6.64 vs $4.67 consensus and raised FY2026 EBITDA and EPS guidance.
Ticker impact
Tenet Healthcare reported Q3 earnings that beat estimates and raised full-year guidance, causing a 2% pre‑market price rise.
likely upward pressure as investors price in the improved outlook
The beat was $1.97 above EPS consensus and guidance was raised by $195 M at the midpoint, a material improvement.
Market effects
Healthcare services sector may see modest upside as Tenet's results set a positive tone.
U.S. hospital and ambulatory‑care stocks could benefit from the guidance lift.
Limited to U.S. markets; no direct global macro effect.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyTenet Healthcare Corporation
U.S. healthcare services provider reporting earnings.



